The role of implantable cardioverter-defibrillators in patients with continuous flow left ventricular assist devices — A meta-analysis

International Journal of Cardiology

Volumn 222, Issue , 2016, Pages 379-384

  Agrawal, Sahil ^a   Garg, Lohit ^b   Nanda, Sudip ^a   Sharma, Abhishek ^c   Bhatia, Nirmanmoh ^d   Manda, Yugandhar ^a   Singh, Amitoj ^a   Fegley, Mark ^a   Shirani, Jamshid ^a  

^a ST LUKE S UNIVERSITY HEALTH NETWORK   (United States)

^b WILLIAM BEAUMONT HOSPITAL   (United States)

^c SUNY DOWNSTATE MEDICAL CENTER   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

ICD; Implantable defibrillator; Mortality; Survival; Ventricular arrhythmia left ventricular assist device

Indexed keywords

AGE DISTRIBUTION; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; CONTINUOUS FLOW LEFT VENTRICULAR ASSIST DEVICE; DISEASE DURATION; HEART RIGHT VENTRICLE FAILURE; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; INCIDENCE; META ANALYSIS; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK FACTOR; SEX DIFFERENCE; SURVIVAL RATE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; DIAGNOSIS; HEART ASSIST DEVICE; HEART LEFT VENTRICLE FUNCTION; MORTALITY; OBSERVATIONAL STUDY; SURGERY; TRENDS;

DEFIBRILLATORS, IMPLANTABLE; HEART-ASSIST DEVICES; HUMANS; MORTALITY; OBSERVATIONAL STUDIES AS TOPIC; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84980450860     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.07.257     Document Type: Article

References (32)

1. Kirklin, J.K., Naftel, D.C., Pagani, F.D., et al. Seventh INTERMACS annual report: 15,000 patients and counting. J. Heart Lung Transplant. 34:12 (2015 Dec), 1495–1504.
2. Miller, L.W., Pagani, F.D., Russell, S.D., et al. Use of a continuous-flow device in patients awaiting heart transplantation. N. Engl. J. Med. 357:9 (2007), 885–896.
3. Slaughter, M.S., Rogers, J.G., Milano, C.A., et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N. Engl. J. Med. 361:23 (2009), 2241–2251.
4. Epstein, A.E., DiMarco, J.P., Ellenbogen, K.A., et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines and the Heart Rhythm Society. J. Am. Coll. Cardiol. 61:3 (2013), e6–75.
5. Pedrotty, D.M., Rame, J.E., Margulies, K.B., Management of ventricular arrhythmias in patients with ventricular assist devices. Curr. Opin. Cardiol. 28:3 (2013), 360–368.
6. Kuhne, M., Sakumura, M., Reich, S.S., et al. Simultaneous use of implantable cardioverter-defibrillators and left ventricular assist devices in patients with severe heart failure. Am. J. Cardiol. 105:3 (2010), 378–382.
7. Ziv, O., Dizon, J., Thosani, A., Naka, Y., Magnano, A.R., Garan, H., Effects of left ventricular assist device therapy on ventricular arrhythmias. J. Am. Coll. Cardiol. 45:9 (2005), 1428–1434.
8. Refaat, M., Chemaly, E., Lebeche, D., Gwathmey, J.K., Hajjar, R.J., Ventricular arrhythmias after left ventricular assist device implantation. Pacing Clin. Electrophysiol. 31:10 (2008), 1246–1252.
9. Brenyo, A., Rao, M., Koneru, S., et al. Risk of mortality for ventricular arrhythmia in ambulatory LVAD patients. J. Cardiovasc. Electrophysiol. 23:5 (2012), 515–520.
10. Raasch, H., Jensen, B.C., Chang, P.P., et al. Epidemiology, management, and outcomes of sustained ventricular arrhythmias after continuous-flow left ventricular assist device implantation. Am. Heart J. 164:3 (2012), 373–378.
11. Boilson, B.A., Durham, L.A., Park, S.J., Ventricular fibrillation in an ambulatory patient supported by a left ventricular assist device: highlighting the ICD controversy. ASAIO J. 58:2 (2012), 170–173.
12. Fasseas, P., Kutalek, S.P., Kantharia, B.K., Prolonged sustained ventricular fibrillation without loss of consciousness in patients supported by a left ventricular assist device. Cardiology 97:4 (2002), 210–213.
13. Cantillon, D.J., Tarakji, K.G., Kumbhani, D.J., Smedira, N.G., Starling, R.C., Wilkoff, B.L., Improved survival among ventricular assist device recipients with a concomitant implantable cardioverter-defibrillator. Heart Rhythm. 7:4 (2010), 466–471.
14. Refaat, M.M., Tanaka, T., Kormos, R.L., et al. Survival benefit of implantable cardioverter-defibrillators in left ventricular assist device-supported heart failure patients. J. Card. Fail. 18:2 (2012), 140–145.
15. Garan, A.R., Yuzefpolskaya, M., Colombo, P.C., et al. Ventricular arrhythmias and implantable cardioverter-defibrillator therapy in patients with continuous-flow left ventricular assist devices: need for primary prevention?. J. Am. Coll. Cardiol. 61:25 (2013), 2542–2550.
16. Lee, W., Tay, A., Subbiah, R.N., et al. Impact of implantable cardioverter defibrillators on survival of patients with centrifugal left ventricular assist devices. Pacing Clin. Electrophysiol. 38:8 (2015), 925–933.
17. Enriquez, A.D., Calenda, B., Miller, M.A., Anyanwu, A.C., Pinney, S.P., The role of implantable cardioverter-defibrillators in patients with continuous flow left ventricular assist devices. Circ. Arrhythm. Electrophysiol. 6:4 (2013), 668–674.
18. Stroup, D.F., Berlin, J.A., Morton, S.C., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 283:15 (2000), 2008–2012.
19. Wells, G.A., Shea, B., O'Connell, D., et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses., 2015 Available http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm Accessed March 28, 2015.
20. Feldman, D., Pamboukian, S.V., Teuteberg, J.J., et al. The 2013 international society for heart and lung transplantation guidelines for mechanical circulatory support: executive summary. J. Heart Lung Transplant. 32:2 (2013), 157–187.
21. Bardy, G.H., Lee, K.L., Mark, D.B., Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N. Engl. J. Med. 352:3 (2005 Jan 20), 225–237.
22. Dang, N.C., Topkara, V.K., Mercando, M., et al. Right heart failure after left ventricular assist device implantation in patients with chronic congestive heart failure. J. Heart Lung Transplant. 25 (2006), 1–6.
23. Kormos, R.L., Teuteberg, J.J., Pagani, F.D., et al. Right ventricular failure in patients with the HeartMate II continuous-flow left ventricular assist device: incidence, risk factors, and effect on outcomes. J. Thorac. Cardiovasc. Surg. 139 (2010), 1316–1324.
24. Baumwol, J., Macdonald, P.S., Keogh, A.M., et al. Right heart failure and “failure to thrive” after left ventricular assist device: clinical predictors and outcomes. J. Heart Lung Transplant. 30 (2011), 888–895.
25. Busch, M.C., Haap, M., Kristen, A., Haas, C.S., Asymptomatic sustained ventricular fibrillation in a patient with left ventricular assist device. Ann. Emerg. Med. 57:1 (2011 Jan), 25–28.
26. Salzberg, S.P., Lachat, M.L., von Harbou, K., Zünd, G., Turina, M.I., Normalization of high pulmonary vascular resistance with LVAD support in heart transplantation candidates. Eur. J. Cardiothorac. Surg. 27 (2005), 222–225.
27. Mikus, E., Stepanenko, A., Krabatsch, T., Loforte, A., Dandel, M., Lehmkuhl, H.B., Hetzer, R., Potapov, E.V., Reversibility of fixed pulmonary hypertension in left ventricular assist device support recipients. Eur. J. Cardiothorac. Surg. 40 (2011), 971–977.
28. Riaz, T., Nienaber, J.J., Baddour, L.M., et al. Cardiovascular implantable electronic device infections in left ventricular assist device recipients. Pacing Clin. Electrophysiol. 37:2 (2014 Feb), 225–230.
29. Quesada, A., Almendral, J., Arribas, F., et al. The DATAS rationale and design: a controlled, randomized trial to assess the clinical benefit of dual chamber (DDED) defibrillator. Europace 2 (2004), 142–150.
30. Schron, E.B., Exner, D.V., Yao, Q., et al. Quality of life in the antiarrhythmics versus implantable defibrillators trial: impact of therapy and influence of adverse symptoms and defibrillator shocks. Circulation 105:5 (2002), 589–594.
31. Poole, J.E., Johnson, G.W., Hellkamp, A.S., et al. Prognostic importance of defibrillator shocks in patients with heart failure. N. Engl. J. Med. 359 (2008), 1009–1017.
32. Klug, D., Balde, M., Pavin, D., Hidden-Lucet, F., et al. Risk factors related to infections of implanted pacemakers and cardioverter-defibrillators: results of a large prospective study. Circulation 116:12 (2007), 1349–1355.